Mencía de Lemus, our Spanish delegate, has been appointed as a member of the Committee for Advanced Therapies, representing patients' organisations.
The Committee for Advanced Therapies (CAT) is the European Medicines Agency's (EMA) committee responsible for assessing the quality, safety, and efficacy of advanced therapy medicinal products (ATMPs) and following scientific developments in the field.
Mencía declares: “I am honored with my appointment as a patient representative at the EMA’s Committee for Advanced Therapies. I will do my best to ensure that decisions are being made taking into account the impact they can have on patients, especially in the case of the rare disease community”.
On behalf of SMA Europe, we could not be happier about this appointment which signifies an important step towards meeting our goals of promoting the interests of our community.